MA51658A - Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies - Google Patents
Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathiesInfo
- Publication number
- MA51658A MA51658A MA051658A MA51658A MA51658A MA 51658 A MA51658 A MA 51658A MA 051658 A MA051658 A MA 051658A MA 51658 A MA51658 A MA 51658A MA 51658 A MA51658 A MA 51658A
- Authority
- MA
- Morocco
- Prior art keywords
- synucleinopathies
- antagonist
- treatment
- association including
- association
- Prior art date
Links
- 208000032859 Synucleinopathies Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762483555P | 2017-04-10 | 2017-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51658A true MA51658A (fr) | 2020-12-02 |
Family
ID=63792736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051658A MA51658A (fr) | 2017-04-10 | 2018-04-09 | Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies |
Country Status (14)
Country | Link |
---|---|
US (1) | US11160809B2 (fr) |
EP (1) | EP3609495A4 (fr) |
JP (1) | JP7271437B2 (fr) |
KR (1) | KR20200002899A (fr) |
CN (1) | CN110730662A (fr) |
AU (1) | AU2018251604B2 (fr) |
BR (1) | BR112019021125A2 (fr) |
CA (1) | CA3059418A1 (fr) |
EA (1) | EA201992414A1 (fr) |
IL (2) | IL269875B1 (fr) |
MA (1) | MA51658A (fr) |
MX (1) | MX2019012088A (fr) |
TW (1) | TWI803488B (fr) |
WO (1) | WO2018191160A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA49524A (fr) | 2017-06-30 | 2021-05-26 | Chase Therapeutics Corp | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE45735T1 (de) | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel. |
US5807867A (en) | 1991-05-31 | 1998-09-15 | Pfizer Inc. | Quinuclidine derivatives |
US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
DE4241013A1 (de) * | 1992-12-05 | 1994-06-09 | Boehringer Ingelheim Kg | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
DE69731658T2 (de) * | 1996-12-02 | 2005-12-01 | Merck Sharp & Dohme Ltd., Hoddesdon | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen |
DE19830201A1 (de) * | 1998-07-07 | 2000-01-13 | Boehringer Ingelheim Pharma | Mittel mit antidepressiver Wirkung |
CA2301899C (fr) * | 1998-07-27 | 2008-11-18 | Boehringer Ingelheim Pharma Kg | Agent antidepresseur |
SE1035115T5 (sv) | 1999-02-24 | 2015-08-04 | Hoffmann La Roche | 4-fenylpyridin-derivat och deras anvaendning som NK-1 receptor-antagonister |
GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
PL205207B1 (pl) | 2000-07-14 | 2010-03-31 | Hoffmann La Roche | N-tlenki pochodnych 4-fenylopirydyny środek leczniczy, sposób wytwarzania tych N-tlenków i ich zastosowanie |
GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
JP4116436B2 (ja) | 2000-12-14 | 2008-07-09 | エフ.ホフマン−ラ ロシュ アーゲー | 自己乳化脂質マトリックス(selm) |
PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
GB0310881D0 (en) * | 2003-05-12 | 2003-06-18 | Merck Sharp & Dohme | Pharmaceutical formulation |
AR047439A1 (es) | 2004-01-27 | 2006-01-18 | Merck & Co Inc | Antagonistas del receptor hidroisoindolina taquiquinina |
LT1713504T (lt) | 2004-01-30 | 2017-09-11 | Zoetis Services Llc | Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms |
US20120253047A1 (en) | 2004-03-19 | 2012-10-04 | Dipharma S.P.A. | Process for the preparation of (r)-pramipexole |
US8604200B2 (en) * | 2005-03-08 | 2013-12-10 | Janssen Pharmaceutica N.V. | Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists |
JP2009500452A (ja) | 2005-07-11 | 2009-01-08 | メルク エンド カムパニー インコーポレーテッド | ヒドロイソインドリンタキキニン受容体アンタゴニストの製造方法 |
EP1917014B1 (fr) | 2005-08-15 | 2009-10-07 | University Of Virginia Patent Foundation | Neurorestauration avec du pramipexole r(+) |
US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
WO2007137071A2 (fr) | 2006-05-16 | 2007-11-29 | Knopp Neurosciences, Inc. | Compositions de r(+) et s(-) pramipéxole et procédés d'utilisation de celles-ci |
CN101641096A (zh) * | 2006-12-14 | 2010-02-03 | 诺普神经科学股份有限公司 | (r)-普拉克索的组合物以及使用该组合物的方法 |
JP2010521493A (ja) | 2007-03-14 | 2010-06-24 | ノップ ニューロサイエンシーズ、インク. | (6r)−4,5,6,7−テトラヒドロ−n6−プロピル−2,6−ベンゾチアゾール−ジアミンの放出調節製剤およびそれらの使用方法 |
US20080254117A1 (en) | 2007-04-10 | 2008-10-16 | Noel Cotton | Process for preparing pramipexole dihydrochloride tablets |
GB0806652D0 (en) | 2008-04-11 | 2008-05-14 | Glaxo Group Ltd | Anhydrous crystal form of orvepitant maleate |
EP3143996A1 (fr) | 2009-08-14 | 2017-03-22 | OPKO Health, Inc. | Préparations intraveineuses d'antagonistes de neurokinine-1 |
EP2722045B1 (fr) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions pour traiter les nausées et vomissements à médiation centrale |
WO2012140604A1 (fr) | 2011-04-15 | 2012-10-18 | Sandoz Ag | Formulations stables de chlorhydrate de pramipexole |
WO2012175434A1 (fr) | 2011-06-20 | 2012-12-27 | Glaxo Group Limited | Formulations pharmaceutiques comprenant du vestipitant |
JP2016532660A (ja) | 2013-10-08 | 2016-10-20 | イノファーマ インク | アプレピタント経口液体製剤 |
WO2016044784A1 (fr) | 2014-09-19 | 2016-03-24 | Heron Therapeutics, Inc. | Formulations d'émulson d'aprépitant |
US9850267B2 (en) | 2015-06-03 | 2017-12-26 | Navinta, Llc | Crystalline fosaprepitant dicyclohexylamine salt and its preparation |
NL2015865B1 (en) | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
MA49524A (fr) | 2017-06-30 | 2021-05-26 | Chase Therapeutics Corp | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression |
-
2018
- 2018-04-09 EA EA201992414A patent/EA201992414A1/ru unknown
- 2018-04-09 MX MX2019012088A patent/MX2019012088A/es unknown
- 2018-04-09 JP JP2019555469A patent/JP7271437B2/ja active Active
- 2018-04-09 IL IL269875A patent/IL269875B1/en unknown
- 2018-04-09 KR KR1020197033121A patent/KR20200002899A/ko unknown
- 2018-04-09 IL IL309770A patent/IL309770A/en unknown
- 2018-04-09 CN CN201880036987.9A patent/CN110730662A/zh active Pending
- 2018-04-09 CA CA3059418A patent/CA3059418A1/fr active Pending
- 2018-04-09 US US16/604,468 patent/US11160809B2/en active Active
- 2018-04-09 AU AU2018251604A patent/AU2018251604B2/en active Active
- 2018-04-09 BR BR112019021125-0A patent/BR112019021125A2/pt not_active Application Discontinuation
- 2018-04-09 WO PCT/US2018/026699 patent/WO2018191160A1/fr unknown
- 2018-04-09 EP EP18785191.0A patent/EP3609495A4/fr active Pending
- 2018-04-09 MA MA051658A patent/MA51658A/fr unknown
- 2018-04-10 TW TW107112324A patent/TWI803488B/zh active
Also Published As
Publication number | Publication date |
---|---|
CA3059418A1 (fr) | 2018-10-18 |
US20200147097A1 (en) | 2020-05-14 |
MX2019012088A (es) | 2020-02-07 |
AU2018251604A1 (en) | 2019-11-21 |
EP3609495A4 (fr) | 2020-12-02 |
TWI803488B (zh) | 2023-06-01 |
IL269875A (fr) | 2019-12-31 |
BR112019021125A2 (pt) | 2020-05-12 |
JP2020516625A (ja) | 2020-06-11 |
IL269875B1 (en) | 2024-02-01 |
EA201992414A1 (ru) | 2020-03-16 |
JP7271437B2 (ja) | 2023-05-11 |
IL309770A (en) | 2024-02-01 |
EP3609495A1 (fr) | 2020-02-19 |
WO2018191160A1 (fr) | 2018-10-18 |
AU2018251604B2 (en) | 2022-04-14 |
KR20200002899A (ko) | 2020-01-08 |
CN110730662A (zh) | 2020-01-24 |
TW201841634A (zh) | 2018-12-01 |
US11160809B2 (en) | 2021-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46098A (fr) | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r | |
BR112018014222A2 (pt) | método de tratamento da glomerulopatia c3 | |
IL276383B1 (en) | Treatment of ophthalmological diseases | |
MA44126A (fr) | Méthodes de traitement de maladies et troubles pulmonaires | |
EA201791901A1 (ru) | Антагонисты рецептора нейрокинина-3 для терапевтического или косметологического лечения излишних жировых отложений на теле | |
MA46061A (fr) | Traitement ascaroside de maladies auto-immunes et inflammatoires | |
MA48730A (fr) | Compositions et méthodes de traitement de synucléinopathies | |
MA41462A (fr) | Méthode de traitement de maladies | |
PL3299810T3 (pl) | Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm) | |
MA42930A (fr) | Traitement de maladies neurodégénératives | |
MA53741A (fr) | Procédés de traitement de troubles myéloprolifératifs | |
EA201792610A1 (ru) | Способ лечения неврологического заболевания | |
MA48862A (fr) | Méthode de traitement de tumeur immunothérapeutique | |
DK3368058T3 (da) | Fremgangsmåde til induktion af kardiocytproliferation og behandling af hjertesygdomme | |
FR3022139B1 (fr) | Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee | |
FR3034320B1 (fr) | Sonde oculaire de traitement par ultrasons | |
HUE056739T2 (hu) | Páciensek kezelése rivaroxaban és verapamil együttes beadásával | |
MA51295A (fr) | Dosage, procédé et traitement d'alpha-synucléinopathies | |
MA51658A (fr) | Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies | |
MA49040A (fr) | Procédés de prévention ou de traitement de maladies ophtalmiques | |
MA41782A (fr) | Traitement de patients atteints de diabète de type 2 | |
MA45245A (fr) | Méthode de traitement de maladie intestinale inflammatoire | |
MA56179A (fr) | Traitement de synucléinopathies | |
EA201891351A1 (ru) | Вспениваемая композиция галобетазола и способ её применения | |
FR3049081B1 (fr) | Procede de traitement de mesures physiques et/ou physiologiques par un terminal mobile |